Drug intelligence / Profile preview

AZD0186

Development stage: Discontinued
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD0186 is an investigational small molecule drug developed by AstraZeneca as an oral agonist of the glucagon-like peptide 1 receptor (GLP-1R). Its mechanism of action involves activating the GLP-1 receptor, which plays a key role in regulating insulin secretion and glucose metabolism. The drug was primarily developed for the treatment of type 2 diabetes. Clinical development reached Phase 1 trials but was discontinued after disappointing results. As a GLP-1R agonist, AZD0186 aimed to compete with other drugs in this class for glycemic control in diabetes.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on AZD0186.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD0186.

Explore the full profile